SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment
9 references·1 citing·45 second hop
Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment (2009)Initial effects of a reimbursement restri…Health systems in transition. (2010)Health systems in transition.Soft regulations in pharmaceutical policy making (2009)Soft regulations in pharmaceu…Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance (2009)Multifaceted national and reg…Recent National and Regional Drug Reforms in Sweden (2008)Recent National and Regional …Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2006)Pharmaceutical policies: effe…Swedish healthcare under pressure (2005)Swedish healthcare under pres…Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (2005)Regulating Pharmaceuticals in…Regulating pharmaceuticals in Europe : striving for efficiency, equity and quality (2004)Regulating pharmaceuticals in…A Critical Analysis of Studies of State Drug Reimbursement Policies: Research in Need of Discipline (1993)A Critical Analysis of Studie…Forecasting drug utilization and expenditure in a metropolitan health region (2010)Forecasting drug utilization …Revisiting the Behavioral Model and Access to Medical Care: Does it Matter? (1995)What does 'access to health care' mean? (2002)Inequalities in access to medical care by income in developed countries (2006)Bulgaria health system review. (2012)Five types of OECD healthcare systems: Empirical results of a deductive classification (2013)The Industrial Organization of Health-Care Markets (2015)INTERRUPTED TIME SERIES DESIGNS IN HEALTH TECHNOLOGY ASSESSMENT: LESSONS FROM TWO SYSTEMATIC REVIEWS OF BEHAVIOR CHANGE STRATEGIES (2003)Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration (2008)Pharmaceutical policies: effects of cap and co-payment on rational drug use (2008)GRADE guidelines: 3. Rating the quality of evidence (2011)Cost-Containment Policies in Public Pharmaceutical Spending in the EU (2012)Policies to promote use of generic medicines in low and middle income countries: A review of published literature, 2000–2010 (2012)The economics of moral hazard: comment (1982)The price of innovation: new estimates of drug development costs (2003)UNCERTAINTY AND THE WELFARE ECONOMICS OF MEDICAL CARE (2003)Competition in off-patent drug markets: Issues, regulation and evidence (2008)What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries (2008)Pharmaceutical policies in European countries in response to the global financial crisis (2011)Institutionalized Organizations: Formal Structure as Myth and Ceremony (1977)The Audit Society: Rituals of Verification (1998)The Audit Society: Rituals of Verification (1999)Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe? (2010)Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications (2012)Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries (2013)National Institute for Clinical Excellence and its value judgments (2004)Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures (2005)Insight into recent reforms and initiatives in Austria: implications for key stakeholders (2008)Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications (2010)European countries with small populations can obtain low prices for drugs: Lithuania as a case history (2011)Institutions, Institutional Change and Economic Performance (1990)Institutions, Institutional Change and Economic Performance (1991)Equity in the delivery of health care in Europe and the US (2000)Market-Oriented, Demand-Driven Health Care Reforms and Equity in Health and Health Care Utilization in Sweden (2009)The Swedish Council on Technology Assessment in Health Care (1989)Ongoing pharmaceutical reforms in France (2010)Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications (2011)Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? (2014)Diffusion of Innovations 1 (2019)The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982?2001 (2003)Cost of Cancer Care: Issues and Implications (2007)2008 FDA drug approvals (2009)Pharmaceutical policies: effects of financial incentives for prescribers (2015)Inadequate Prescription-Drug Coverage for Medicare Enrollees — A Call to Action (1999)Transforming Insurance Coverage Into Quality Health Care (2000)Effective healthcare cost-containment policies: A systematic review (2018)
this work references cited by second hop

References

  • 2010Health systems in transition.600 cited
  • 2006Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies206 cited
  • 1993A Critical Analysis of Studies of State Drug Reimbursement Policies: Research in Need of Discipline169 cited
  • 2004Regulating pharmaceuticals in Europe : striving for efficiency, equity and quality162 cited
  • 2005Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality155 cited
  • 2009Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance150 cited
  • 2005Swedish healthcare under pressure107 cited
  • 2009Soft regulations in pharmaceutical policy making97 cited
  • 2008Recent National and Regional Drug Reforms in Sweden85 cited

Cited by

  • 2010Forecasting drug utilization and expenditure in a metropolitan health region70 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work